Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

Abstract

In agreement with preclinical and clinical studies, AERS analysis is consistent with an association between pioglitazone and bladder cancer. This issue needs constant epidemiologic surveillance and urgent definition by more specific studies.